Navlimetostat

Navlimetostat

Navlimetostat
Clinical data
Other namesMRTX-1719
Identifiers
  • (2M)-2-{4-[4-(Aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl]-1-methyl-1H-pyrazol-5-yl}-4-chloro-6-(cyclopropyloxy)-3-fluorobenzonitrile
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
Chemical and physical data
FormulaC23H18ClFN6O2
Molar mass464.89 g·mol−1
3D model (JSmol)
  • CN1C(=C(C=N1)C2=CC3=C(C=C2)C(=O)NN=C3CN)C4=C(C(=CC(=C4F)Cl)OC5CC5)C#N
  • InChI=InChI=1S/C23H18ClFN6O2/c1-31-22(20-15(8-26)19(33-12-3-4-12)7-17(24)21(20)25)16(10-28-31)11-2-5-13-14(6-11)18(9-27)29-30-23(13)32/h2,5-7,10,12H,3-4,9,27H2,1H3,(H,30,32)
  • Key:BZKIOORWZAXIBA-UHFFFAOYSA-N

Navlimetostat is an investigational new drug that is being evaluated by Mirati Therapeutics abd Bristol-Myers Squibb for the treatment of adenocarcinoma.[1] It is a PRMT5 protein inhibitor.[1][2][3]

References

  1. ^ a b "Navlimetostat - Bristol-Myers Squibb". AdisInsight. Springer Nature Switzerland AG. Retrieved 5 July 2026.
  2. ^ Smith CR, Aranda R, Bobinski TP, Briere DM, Burns AC, Christensen JG, et al. (February 2022). "Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers". Journal of Medicinal Chemistry. 65 (3): 1749–1766. doi:10.1021/acs.jmedchem.1c01900. PMID 35041419.
  3. ^ Jeong Y, Cho Y, Kim YK (April 2026). "Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities". Journal of Biomedical Science. 33 (1) 37. doi:10.1186/s12929-026-01240-3. PMC 13047808. PMID 41928257.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.